title: OC-12 - Peri operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice.
abstract: BACKGROUND
  Gynaecological cancer is associated with some of the highest rates of venous thromboembolism (VTE) with some subtypes of ovarian cancer associated with rates as high as 20%. VTE prophylaxis is an important part of post-operative management in gynaecological cancer patient care. Despite the evidence base and guidelines recommending extended VTE prophylaxis for patients undergoing major cancer surgery, adherence to best practice guidelines has been found to be low.
  
  
  OBJECTIVE
  The aim of this study is to assess gynaecological oncologist's awareness of the guidelines surrounding VTE prophylaxis for post-operative gynaecological cancer patients and to determine the type and duration of VTE prophylaxis implemented by gynaecological oncologists.
  
  
  METHODS
  The study used the European Society Gynaecology Oncology (ESGO) membership as the population studied. ESGO is a multidisciplinary, non-profit association, founded in 1983. ESGO consisit of more than 1800 professional of different specialities dealing with gynaecological oncology. The e mail address of 650 member were avilable on the ESGO website. We send a Survey Monkey link to the questionnaire by email to a total of 650 ESGO member whose email addresses were obtained from the ESGO directory. 205 e mails returned back as the email used was invalied, only 445 e mail successfully delivered. The survey remained open for 44 days. Results were analysed on Survey Monkey.
  
  
  RESULTS
  A 59.3% of respondents said that they decided upon appropriate VTE prophylaxis for a patient according to national/international best practice guidelines. A further 39.4% respondents said that they made their choice based upon clinical judgement. 59.8% of respondents said that they begin VTE prophylaxis pre-operatively for the high risk patients. 6.1% said that they begin prophylaxis in the operating theatre, 18.9% begin prophylaxis 6 hours post-operatively and 9.1% begin prophylaxis 12 hours post-operatively. The remaining respondents said that they begin VTE more than 24 hours post operatively 44.7% said that they prescribe VTE prophylaxis for 4 weeks. A further 15.9% said that they prescribe VTE prophylaxis for 6 weeks and 4.75% for longer than 6 weeks.
  
  
  CONCLUSIONS
  In conclusion, the adherence to current guidelines for VTE prophylaxis in the peri-operative period for gynaecological oncology patients is still poor. Awareness needs to be raised in order to decrease the morbidity/mortality of VTE in this high risk group of patients. The adoption of multidiscplinary approach to manage gynaecological cancer patients, which includes the involvment of thrombosis specialist, may reduce post operative VTE rates and improve cancer care.
authors.affiliation: Department of Gynaecology oncology, St. James's Hospital, Dublin, Ireland.
authors.forename: S
authors.initials: S
authors.lastname: Petch
authors.affiliation: Department of Gynaecology oncology, St. James's Hospital, Dublin, Ireland.
authors.forename: L A
authors.initials: LA
authors.lastname: Norris
authors.affiliation: Department of Gynaecology oncology, St. James's Hospital, Dublin, Ireland.
authors.forename: S A
authors.initials: SA
authors.lastname: O'Toole
authors.affiliation: Department of Gynaecology oncology, St. James's Hospital, Dublin, Ireland.
authors.forename: N
authors.initials: N
authors.lastname: Gleeson
authors.affiliation: Department of Gynaecology oncology, St. James's Hospital, Dublin, Ireland.
authors.forename: F Abu
authors.initials: FA
authors.lastname: Saadeh